Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,240 total articles
Crown Holdings' sizable free cash flow and solid return on equity support a buy-rated trade. Valuation metrics - P/E ~13.5, EV/EBITDA ~11.7 and price/free cash flow ~12.7 - leave room for a re-rating if commodity costs stabilize and beverage demand holds. Technicals and dividend support create a favorable entry around $110 with a clear stop under n…
W&T Offshore (WTI) is a small-cap Gulf of Mexico producer with a levered balance sheet and a cheap trading multiple. If oil prices regain momentum, WTI stands to re-rate quickly — but the trade carries execution and credit risk. This plan lays out a mid-term swing trade (45 trading days) that targets a run past last year’s highs while capping downs…
Amazon fell into a broad AI-capex panic despite AWS showing healthy monetization and high margins. The stock is oversold (RSI ~27), trading well below its moving averages, and the pullback offers a controlled, asymmetric trade with a mid-term horizon. Entry at $205.65, stop at $195.00, target $255.00.
Merck (MRK) is a pragmatic buy into 2026. The stock trades at roughly a mid-teens P/E, produces strong free cash flow ($13.05B), and still benefits from Keytruda momentum and an expanding animal health business. Near-term guidance that missed Street estimates and binary clinical readouts create a time-sensitive window—the fundamentals argue for acc…
Veeva Systems is deep in oversold territory after a sharp pullback. Strong free cash flow, a fresh $2 billion buyback, and an expanding addressable market for regulated cloud workflows argue for a mean-reversion trade. This idea lays out a precise entry, stop and target with rationale and risks.
Workday (WDAY) has been punished by a negative narrative around workforce moves and activist exits, but the business still generates meaningful free cash flow, has a healthy balance sheet, and sits at technically oversold levels. This trade idea lays out five reasons to buy, a concrete entry/stop/target plan for a mid-term (45 trading days) swing, …
Kroger (KR) looks attractive as a long trade for risk-conscious investors. The business generates meaningful free cash flow ($2.27B) and returns capital through dividends (next payable 03/01/2026). Recent operational catalysts - from automation in cold-chain warehouses to expanded AI personalization - should lift margins and customer retention over…
Arm's licensing model sits at the orchestration layer of an AI stack pivot toward distributed, power-efficient compute. With data-center royalties more than doubling YoY and hyperscaler capex commitments, Arm can convert model scale into recurring, high-margin revenue. Valuation is rich today, so the trade uses a disciplined entry and stop to captu…
Rubrik (RBRK) is an industry fixture in cloud data management and cyber recovery. Shares have retraced from last summer’s highs and are trading near technical oversold levels while the company shows improving subscription momentum and positive free cash flow. This is a disciplined, catalyst-driven buy: enter at $50.00, stop at $44.00, primary targe…
NetScout's mix of strong free cash flow, negligible debt, and incremental AI/ML enhancements to its nGeniusONE platform support a tactical long. Valuation looks reasonable (P/E ~20.8, EV/EBITDA ~8.6) and the balance sheet is clean; if management converts recent operational work into margin expansion, shares can re-rate toward consensus analyst upsi…
We upgrade Bar Harbor Bankshares (BHB) to Buy. The story here is modest: a reasonably valued regional bank (market cap ~$595M) trading slightly above its longer-term moving averages, an attractive dividend yield (~3.5%), and consecutive quarter earnings beats that point to operating stability. Our trade is a mid-term swing targeting renewed P/E exp…
Rubrik plunged with the broader software selloff but still shows double-digit ARR growth, positive free cash flow and an attractive risk/reward. I recommend buying RBRK with a tight stop and a clear target as sector sentiment normalizes and Zero Trust spending accelerates.
Biogen reported stable FY25 earnings and a Q4 beat, with Alzheimer's therapy Leqembi driving growth while legacy multiple sclerosis drugs decline. Valuation looks reasonable (market cap ~$29.5B, P/E ~22.8) and free cash flow is healthy, but MS franchise pressure and execution risk argue for a controlled, horizon-based trade rather than an aggressiv…
Selective Insurance combines a low-leverage balance sheet, double-digit ROE and strong free cash flow with modest valuation. We set a swing trade that captures likely re-rating from improving underwriting/premium momentum and higher investment income while limiting downside with a clear stop.
Pacira is a specialty pain-management business trading at a sub-$1B market cap with robust free cash flow and a concentrated, durable product franchise. Recent Paragraph IV litigation headlines and a securities suit have pushed sentiment and elevated short interest, but the commercial moat and cash generation argue for a long trade while the legal …
Equinix sits at the center of the AI and cloud infrastructure boom: 273 global data centers, record bookings, and a multi-year expansion plan funded with ample liquidity. At a market cap near $84B and an EV of roughly $100.7B, the stock offers exposure to hyperscaler capex with a 2.2% dividend while still trading at elevated multiples. This trade i…
Thomson Reuters (TRI) is a subscription-heavy, wide-moat information business trading near its 52-week low after a sharp market re-rating. The fundamentals - sticky legal, tax and regulatory workflows - remain intact, dividends are coming, and technicals show extreme oversold conditions. This trade idea recommends a tactical long entry to capture a…
Intuit has been punished alongside software peers as AI fears and a sector rotation drove a fast decline. Fundamentals - recurring revenue, 18% recent top-line growth and $6.4B free cash flow - remain intact. Technicals show extreme oversold readings and elevated short activity. This trade idea lays out a disciplined, mid-term long with clear entri…
Fugro’s business has been hit by a brutal energy-capex reset that erased growth momentum. The market’s reaction and extreme short interest have pushed the share structure into a state where a catalyst-driven recovery would produce outsized returns. Technicals show momentum, but liquidity is thin and momentum is extended. This is a tactical long wit…
PepsiCo remains a high-quality consumer staple with steady cash generation, a rising dividend and fresh strategic initiatives supported by a $4 billion activist investment. Fundamentals justify a constructive stance, but technicals are extended and the company carries meaningful leverage. Maintain Buy, but wait for a disciplined entry.
Amcor (AMCR) offers a rare mix for income investors: a dividend yield north of 5% on a $22.2B market cap company with recurring cash flow and secular packaging tailwinds. The business is cyclical but defensive by virtue of exposure to grocery, healthcare, and e-commerce packaging. We outline a long trade plan (entry $47.50, stop $44.00, target $55.…
Dollar Tree (DLTR) has rallied from its 2025 low but still offers a favorable risk/reward. Recent multi-price execution lifted sales and margins, Q3 2025 showed 9.4% net sales growth and an EPS beat, and the company generates meaningful free cash flow. At a market cap near $24.6B and EV/EBITDA ~12.8, the stock looks priced for modest growth, not th…
Microsoft (MSFT) pulled back sharply into oversold territory while fundamental earners - Azure, Microsoft 365, and free cash flow - remain intact. At ~2.98T market cap and ~25x earnings, the stock looks buyable for a mid-term swing (45 trading days) with a clear entry, stop and target that respect both momentum and valuation risk.
Merck is no longer the deeply discounted defensive name it was in mid-2025. After a strong run to a 52-week high and a guidance miss that leaves upside dependent on sustained Keytruda growth and strategic execution, we downgrade the stock and propose a mid-term short-biased trade to capture a likely pullback.
Starbucks reported early signs of a turnaround with improving comparable-store sales and a clear international expansion plan. The stock has run, but momentum remains intact and the valuation is tolerable given FCF generation and a large TAM. This trade proposes a mid-term tactical long at $99.50 with a $112 target and a $94 stop, sized for a mediu…
